PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
July 5, 2026Cancer Immunology Research0 citationsOpen Access

Enhancement of ferroptosis in escape variant tumor cells by IFN-γ derived from antigen-specific T cells controls tumor with heterogeneity

View Full Paper
DEDaisuke EharaKYKiyoshi YasuiMYMitsuhiro Yoneda

Key Points

  • This research investigates whether combining immunotherapy with ferroptosis inducers can target escape variant tumor cells.
  • Combined RSL3, a ferroptosis inducer, with MART-1-specific TCR-T cells in a heterogeneous tumor model.
  • Utilized human melanoma cells and β2 microglobulin knockout counterparts in NOG mice to assess treatment efficacy.
  • Combination therapy resulted in significant tumor reduction in models with both antigen-positive and negative cells.
  • Achieved a notable antitumor effect, suggesting potential for overcoming tumor heterogeneity in immunotherapy.

Abstract

Tumor masses often exhibit heterogeneity, including escape variant clones that lack antigen-presenting machinery and/or tumor antigens, which poses a major challenge to immunotherapy. Ferroptosis, a form of regulated cell death driven by iron-dependent lipid peroxidation, has been shown to effectively induce cell death in various tumor cells. Recent studies have reported that IFN-γ suppresses the expression of System Xc-, thereby enhancing the induction of ferroptosis. Based on this, we hypothesized that combining immunotherapy with ferroptosis inducers could enhance antitumor effects against both antigen-positive and antigen-negative tumor cells. We found that combining RSL3, a ferroptosis inducer, with MART-1-specific TCR-T cells eradicates a heterogeneous tumor model consisting of human melanoma cells and their β2 microglobulin knockout counterparts. In NOG mice, this combination therapy demonstrates a significant antitumor effect against tumors with heterogeneity. These findings suggest that integrating ferroptosis inducers with immunotherapy could overcome the limitations imposed by escape variant tumor clones, offering a promising strategy for cancer treatment.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ehara et al. (2026) studied this question.

synapsesocial.com/papers/6a49f70df5d1d45b2880120bhttps://doi.org/10.1158/2326-6066.cir-25-0175
Ask AI
Helpful
Bookmark
Share
View Full Paper